227793 - RFEI 2026-27-001 - Cara Centre Pharmacy Services (Канада - Тендер #71842640) | ||
| ||
| Для перевода текста тендера на нужный язык воспользуйтесь приложением: | ||
Страна: Канада (другие тендеры и закупки Канада) Организатор тендера: www.merx.com Номер конкурса: 71842640 Дата публикации: 14-04-2026 Источник тендера: www.merx.com |
||
Expression of Interest requested for qualified organizations to provide comprehensive Pharmacy Services for a tertiary mental health facility, including prescription medications, clinical pharmacist consultation, and 24/7 on-call availability.
00004996144
Issuing OrganizationInterior Health Authority
Solicitation TypeEOI - Expression of Interest (Informal)
Solicitation Number227793
TitleRFEI 2026-27-001 - Cara Centre Pharmacy Services
Source IDSCRIBE
British Columbia
Purchase TypeNot Stated
2026/04/14 10:01:00 AM EDT
Closing Date2026/04/27 05:00:00 PM EDT
Bryonie Montagliani
RequestsForProposals@interiorhealth.ca
Interior Health Authority is requesting Expressions of Interest (RFEI) from qualified organizations able to provide Pharmacy Services to Cara Centre in the community of Kelowna, BC.
Tertiary Mental Health Pharmacy Services include provision of prescription medications, over-the-counter medications (OTC"s), and stock or contingency medications and associated supplies as
well as clinical pharmacist review and consultation, on a day-to-day and urgent services basis. Services also maintaining a complete medication profile for each client as well as medication
profiles and medication administrations records (MAR’s) as required and ensure compliance with the Authority standards, client medication reconciliations, medication room audits, and
participation in multi-disciplinary rounds. Services are required for day-to-day and urgent pharmacy services inclusive of delivery during the organization’s operating hours, and on-call
availability 24/7 365 days a year, if and where required on an emergent basis. Cara Centre supports clients with complex mental health and substance use conditions. Provision of opioid agonist
therapy will be required.